Edition:
India

NewLink Genetics Corp (NLNK.OQ)

NLNK.OQ on NASDAQ Stock Exchange Global Market

5.19USD
1:30am IST
Change (% chg)

$-0.16 (-2.99%)
Prev Close
$5.35
Open
$5.34
Day's High
$5.41
Day's Low
$5.14
Volume
167,389
Avg. Vol
249,133
52-wk High
$19.30
52-wk Low
$3.76

Latest Key Developments (Source: Significant Developments)

Newlink Genetics Outlines 2018 Business Priorities
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Newlink Genetics Corp ::NEWLINK GENETICS OUTLINES 2018 BUSINESS PRIORITIES TO SUPPORT PHASE 3 PIVOTAL TRIAL OF INDOXIMOD PLUS PD-1 INHIBITORS.NEWLINK GENETICS CORP - ENDED 2017 WITH APPROXIMATELY $158 MILLION IN CASH AND CASH EQUIVALENTS.NEWLINK GENETICS - ENTERING 2018, HAVE ALIGNED BUSINESS AND INVESTMENTS TO DRIVE INDIGO301 AND OTHER HIGH-POTENTIAL DEVELOPMENT PROGRAMS.NEWLINK GENETICS CORP - ENROLL MAJORITY OF INDIGO301 TRIAL BY END OF 2018.NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + PD-1 BLOCKADE IN ADVANCED MELANOMA EXPECTED IN 2018.NEWLINK GENETICS CORP - PHASE 2 RESULTS FOR INDOXIMOD + GEM/NAB-PACLITAXEL IN PANCREATIC CANCER EXPECTED 1H 2018.NEWLINK GENETICS CORP - PHASE 2 RANDOMIZED ASTRAZENECA COLLABORATION IN PANCREATIC CANCER TO INITIATE 1H 2018.  Full Article

Newlink Genetics, Bps And Merck Sharp & Dohme Amended License & Collaboration Agreement
Tuesday, 12 Dec 2017 

Dec 11 (Reuters) - Merck & Co Inc ::NEWLINK GENETICS - ON DEC 5, BPS AND MERCK SHARP & DOHME CORP AMENDED LICENSE & COLLABORATION AGREEMENT DATED NOV 21, 2014.NEWLINK GENETICS-UNDER MERCK AMENDMENT, MODIFIED MERCK'S SUBLICENSE OF IP RIGHTS UNDER PHAC LICENSE AGREEMENT TO BE NON-EXCLUSIVE ON EBOLA SUDAN FIELD OF USE.NEWLINK GENETICS - AMENDMENT ALSO ADJUSTS EXPIRATION OF MERCK'S OBLIGATION TO PAY ROYALTIES TO BPS BASED ON ROYALTY TERM OF PHAC LICENSE AGREEMENT.  Full Article

NewLink Genetics reports Q3 loss per share $0.69
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - NewLink Genetics Corp :Q3 loss per share $0.69.NewLink Genetics Corp - ‍Expect to end 2017 with approximately $150 million in cash and equivalents​.NewLink Genetics Corp - Qtrly ‍total operating revenues $5.5 million versus $15.3 million.Q3 earnings per share view $-0.74, revenue view $3.4 million -- Thomson Reuters I/B/E/S.  Full Article

Newlink genetics announces FDA orphan-drug designation for Indoximod
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Newlink Genetics Corp :Newlink Genetics announces FDA orphan-drug designation for Indoximod.‍Indoximod was granted orphan-drug designation by U.S. FDA for treatment of patients with stage IIB-IV melanoma​.  Full Article

NewLink Genetics Q3 loss $0.54/shr
Tuesday, 1 Nov 2016 

Newlink Genetics Corp : NewLink Genetics Corp says expects to have approximately $132 million in cash and equivalents on December 31, 2016 . NewLink Genetics Corp - qtrly loss per share $0.54 . Q3 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S .Press release - NewLink Genetics Corp provides operational update and reports third quarter 2016 financial results.  Full Article

Newlink Genetics Q2 loss per share $1.12
Friday, 29 Jul 2016 

Newlink Genetics Corp : Q2 loss per share $1.12 . Implemented a significant restructuring program following may results of impress phase 3 study of algenpantucel-l . Reducing headcount from approximately 230 to approximately 130 . Recorded $12.3 million in restructuring expenses in q2 . Winding down hyperacute cellular immunotherapy clinical trials that do not include a checkpoint inhibitor combination .In q3, company expects to record small additional charges relating to closing or reduction of leased facilities.  Full Article